Release Date: 2024-06-19

Systemic Chemotherapy for Metastatic Prostate Cancer

Selamettin Demir (Author), Muhammet Cicek (Author)

Release Date: 2024-06-19

The legal framework of alcohol consumption in Turkey is multifaceted and governed by various laws and regulations. This study provides an in-depth analysis of the legal aspects surrounding alcohol consumption in Turkey. It delves into the constitutional, legislative, and regulatory dimensions concerning the production, sale, advertisement, and consumption of alcoholic beverages. The study highlights key [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page69
    Last Page77
    DOIhttps://doi.org/10.69860/nobel.9786053359142.6
    Page Count9
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    This section highlights the current cytotoxic management of prostate cancer. Although cytotoxic treatment agents for prostate cancer have not changed much over the years, new treatment modalities, targeted therapies and imaging advances have led to new approaches to cytotoxic treatment options. Another important consideration when prescribing treatment is the balance between potential side effects and treatment response. Measures of patient quality of life and performance status can guide clinicians in this regard. Overall, future therapies in the systemic treatment of prostate cancer will focus on combination therapies.

    Selamettin Demir (Author)
    MD, Associate Professor of Urology, Van Regional Training and Research Hospital
    https://orcid.org/0000-0003-1302-4127
    3Selamettin Demir has been practising urology for more than fifteen years. In addition to various academic studies, I have publications on urooncology. At the same time, I have a 4-month fellowship service in the field of urooncology at Istanbul Medeniyet University. Currently, I am continuing my academic studies at the University of Health Sciences Van Training and Research Hospital.

    Muhammet Cicek (Author)
    MD, Van Regional Training and Research Hospital
    https://orcid.org/0000-0001-5478-3352
    3Muhammet Çiçek has been working as a specialist in urology for two years. The author, who has contributed to many scientific publications, is currently working at Health Sciences University Van Training and Research Hospital. He is married and has two children.

    • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502-12.

    • Partin AW, Peters CA, Kavoussi LR, Dmochowski RR, Wein AJ. Campbell-Walsh-Wein Urology Twelfth Edition Review E-Book. 2020.

    • James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA oncology. 2016;2(3):348-57.

    • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982;5(6):649-55.

    • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737-46.

    • Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149-58.

    • Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUGAFU15 Trial. European urology. 2016;70(2):256-62.

    • Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. Lancet (London, England). 2022;399(10336):1695-707.

    • Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2022;386(12):1132-42.

    • Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. 2023;21(10):1067-96.

    • Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: LongTerm Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(11):1080-7.

    • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (London, England). 2016;387(10024):1163-77.

    • Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513-20.

    • Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(2):242-5.

    • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London,England). 2010;376(9747):1147-54.

    • Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(28):3198-206.

    • Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. The Lancet Oncology. 2020;21(11):1513-25.

    • Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. The Lancet Oncology. 2019;20(10):1432-43.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!